Provided by Tiger Trade Technology Pte. Ltd.

Abbott Laboratories

98.73
+0.57000.58%
Post-market: 98.31-0.4250-0.43%17:00 EDT
Volume:9.03M
Turnover:890.40M
Market Cap:171.68B
PE:31.95
High:99.37
Open:98.89
Low:97.62
Close:98.16
52wk High:135.13
52wk Low:81.97
Shares:1.74B
Float Shares:1.70B
Volume Ratio:0.95
T/O Rate:0.53%
Dividend:2.48
Dividend Rate:2.51%
EPS(TTM):3.09
EPS(LYR):3.73
ROE:10.58%
ROA:5.33%
PB:3.36
PE(LYR):26.47

Loading ...

Barclays Initiates Coverage on Abbott Laboratories With Overweight Rating, $120 Price Target

MT Newswires Live
·
Yesterday

Barclays Reaffirms Their Buy Rating on Abbott Laboratories (ABT)

TIPRANKS
·
Yesterday

Why Vaxcyte Chose A 1.5% Convertible

Macro World​
·
Yesterday

Perrigo Co. PLC Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Yesterday

Scotts Miracle-Gro Names Prathima Hegde as CIO

Reuters
·
Yesterday

From Lilly Deal to Market Darling: Inside Ginkgo's 120% Monthly Run

Bellwether Stocks Movement
·
Oct 06

Edwards Lifesciences Corp. Stock Underperforms Monday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Oct 06

Medtronic PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 06

Abbott Laboratories Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 06

Abbott Laboratories Stock (ABT) Moved Up by 3.08% on Oct 5: Facts Behind the Movement

TradingKey
·
Oct 06

Movement Alert|Abbott Laboratories Rises 3.07% in Regular Trading, Driven by Analyst Optimism and Regulatory Milestone

Market Focus
·
Oct 06

Abbott Laboratories Receives FDA Approval to Include Interactive Features in CardioMEMS Heart Monitor

MT Newswires Live
·
Oct 05

Abbott Receives FDA Approval for New Cardiomems HF System Capabilities That Help Patients Engage in the Care of Their Heart Condition

THOMSON REUTERS
·
Oct 05

Abbott - Cardioguide HF App and Dynamic Treatment Plan to be Available Later This Year

THOMSON REUTERS
·
Oct 05

Evercore ISI Adjusts Price Target on Abbott Laboratories to $124 From $120, Keeps Outperform Rating

MT Newswires Live
·
Oct 05

One Molecule, Three Diseases, $1.55 Billion — Inside CSL's Bet

Bellwether Stocks Movement
·
Oct 05

Merck Doubled Off Its Lows — And Analysts Still See More Room

Bellwether Stocks Movement
·
Oct 05

CSL Bets $1.6 Billion on a Drug That Hasn't Finished Phase 2

Bellwether Stocks Movement
·
Oct 05

Bayer Bets $2.2 Billion That America Is Still The Best Place To Make Drugs

Macro World​
·
Oct 03

23.3% Vs 14.8%: Lilly's New Data Just Changed The Obesity Drug Playbook

Bellwether Stocks Movement
·
Oct 03